Clinical Trials Browser

Esophageal Squamous Cell Carcinoma

NCT07571551 2026-05-11

TRIPLE-PATH

Phase 2 Recruiting

75 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2 Recruiting

570 enrolled

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05182957 2026-05-01

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Recruiting

31 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07007182 2026-05-01

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Recruiting

54 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07392320 2026-04-24

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Phase 2 Recruiting

142 enrolled

Nasopharangeal Cancer

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

535 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06468280 2026-01-21

ROSETTE

Phase 2 Recruiting

84 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

40 enrolled

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT06008054 2025-09-26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Phase 2 Recruiting

376 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Phase 2 Recruiting

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

55 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2 Recruiting

120 enrolled

CNS

Neuroblastoma

NCT06908031 2025-05-14

CRIT

Phase 2 Recruiting

49 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06437509 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Phase 2 Recruiting

66 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 2 Recruiting

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06471205 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Phase 2 Recruiting

52 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Phase 2 Recruiting

221 enrolled

Gastrointestinal

Locally Recurrent Rectal Cancer

NCT06758037 2025-03-18

HiR+X

Phase 2 Recruiting

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Phase 2 Recruiting

46 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05555888 2025-01-15

TORCH-E

Phase 2 Recruiting

34 enrolled

Gastrointestinal

Early Low Rectal Cancer

NCT05972655 2025-01-09

mRCAT

Phase 2 Recruiting

32 enrolled

Gastrointestinal

Low Rectal Cancer

NCT05628038 2024-10-01

TORCH-R

Phase 2 Recruiting

93 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06455124 2024-06-13

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Phase 2 Recruiting

39 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06170710 2023-12-14

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Phase 2 Recruiting

173 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06121700 2023-11-08

Miracle-G

Phase 2 Recruiting

55 enrolled

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT06122493 2023-11-08

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

48 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

112 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05961761 2023-07-27

PROPANE

Phase 2 Recruiting

80 enrolled

Sarcoma

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Clinical Trials

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

TRIPLE-PATH

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

ROSETTE

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

SPARC

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

CRIT

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

HiR+X

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

TORCH-E

mRCAT

TORCH-R

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Miracle-G

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

PROPANE